Total Payments
$8,965
2024 Payments
$22.41
Companies
12
Transactions
30
Medicare Patients
985
Medicare Billing
$222,471
Payment Breakdown by Category
Consulting$6,475 (72.2%)
Travel$1,765 (19.7%)
Food & Beverage$659.76 (7.4%)
Education$66.09 (0.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $6,475 | 1 | 72.2% |
| Travel and Lodging | $1,765 | 5 | 19.7% |
| Food and Beverage | $659.76 | 20 | 7.4% |
| Education | $66.09 | 4 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $7,632 | 5 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $919.54 | 6 | $0 (2019) |
| Biogen, Inc. | $144.21 | 3 | $0 (2018) |
| PFIZER INC. | $119.01 | 7 | $0 (2020) |
| Amgen Inc. | $25.75 | 2 | $0 (2019) |
| Kite Pharma, Inc. | $22.98 | 1 | $0 (2022) |
| Medline Industries LP | $22.41 | 1 | $0 (2024) |
| Astellas Pharma US Inc | $21.69 | 1 | $0 (2019) |
| Alexion Pharmaceuticals, Inc. | $16.56 | 1 | $0 (2017) |
| CSL Behring | $14.16 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22.41 | 1 | Medline Industries LP ($22.41) |
| 2022 | $36.48 | 2 | Kite Pharma, Inc. ($22.98) |
| 2020 | $20.53 | 1 | PFIZER INC. ($20.53) |
| 2019 | $144.48 | 8 | Novartis Pharmaceuticals Corporation ($66.57) |
| 2018 | $8,629 | 13 | Celgene Corporation ($7,632) |
| 2017 | $112.81 | 5 | Biogen, Inc. ($70.21) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/11/2024 | Medline Industries LP | — | Food and Beverage | In-kind items and services | $22.41 | General |
| 12/20/2022 | ABBVIE INC. | LUPRON DEPOT (Drug) | Education | In-kind items and services | $13.50 | General |
| Category: ENDOCRINOLOGY | ||||||
| 02/25/2022 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $22.98 | General |
| 01/15/2020 | PFIZER INC. | BOSULIF (Drug), BESPONSA, DAURISMO | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/14/2019 | Astellas Pharma US Inc | CRESEMBA (Drug) | Food and Beverage | In-kind items and services | $21.69 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/06/2019 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $21.31 | General |
| Category: HEMATOLOGY | ||||||
| 10/02/2019 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $11.79 | General |
| Category: Oncology | ||||||
| 07/17/2019 | Amgen Inc. | Blincyto (Biological) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: Oncology | ||||||
| 06/05/2019 | PFIZER INC. | MYLOTARG (Biological), BOSULIF, BESPONSA | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: ONCOLOGY | ||||||
| 05/01/2019 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug), TASIGNA | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: ONCOLOGY | ||||||
| 03/25/2019 | CSL Behring | Hizentra (Biological) | Food and Beverage | Cash or cash equivalent | $14.16 | General |
| Category: Immunology | ||||||
| 02/06/2019 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug) | Food and Beverage | In-kind items and services | $23.06 | General |
| Category: HEMATOLOGY | ||||||
| 11/07/2018 | Celgene Corporation | — | Consulting Fee | Cash or cash equivalent | $6,475.00 | General |
| 10/18/2018 | Celgene Corporation | — | Travel and Lodging | In-kind items and services | $438.96 | General |
| 10/18/2018 | Celgene Corporation | — | Travel and Lodging | In-kind items and services | $348.76 | General |
| 10/18/2018 | Celgene Corporation | — | Travel and Lodging | In-kind items and services | $249.01 | General |
| 10/18/2018 | Celgene Corporation | — | Food and Beverage | In-kind items and services | $120.28 | General |
| 10/10/2018 | PFIZER INC. | MYLOTARG (Biological), BOSULIF, BESPONSA | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: ONCOLOGY | ||||||
| 06/19/2018 | PFIZER INC. | MYLOTARG (Biological), BOSULIF, BESPONSA | Food and Beverage | In-kind items and services | $11.99 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2018 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | Cash or cash equivalent | $74.00 | General |
| Category: NEUROLOGY | ||||||
| 06/07/2018 | PFIZER INC. | MYLOTARG (Biological) | Education | In-kind items and services | $20.05 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2018 | Novartis Pharmaceuticals Corporation | ABL002 (Drug) | Travel and Lodging | In-kind items and services | $170.79 | General |
| 05/18/2018 | Novartis Pharmaceuticals Corporation | ABL002 (Drug) | Food and Beverage | In-kind items and services | $125.18 | General |
| 05/17/2018 | Novartis Pharmaceuticals Corporation | ABL001X (Drug) | Travel and Lodging | In-kind items and services | $557.00 | General |
| 02/20/2018 | PFIZER INC. | MYLOTARG (Biological) | Education | In-kind items and services | $20.05 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 357 | 3,229 | $555,985 | $76,135 |
| 2022 | 9 | 282 | 2,384 | $408,260 | $62,411 |
| 2021 | 8 | 210 | 481 | $201,347 | $43,320 |
| 2020 | 5 | 136 | 443 | $144,384 | $40,605 |
Total Patients
985
Total Services
6,537
Medicare Billing
$222,471
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 89 | 258 | $88,039 | $23,109 | 26.2% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 36 | 202 | $214,928 | $19,664 | 9.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 131 | $68,120 | $17,202 | 25.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $16,925 | $3,803 | 22.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 31 | 278 | $54,488 | $3,217 | 5.9% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 115 | $31,280 | $2,428 | 7.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 12 | 41 | $22,468 | $1,970 | 8.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 12 | 12 | $12,300 | $1,550 | 12.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 16 | 61 | $16,958 | $1,286 | 7.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 11 | 15 | $6,360 | $717.00 | 11.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 18 | 760 | $19,000 | $635.94 | 3.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 41 | $3,772 | $426.00 | 11.3% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 25 | 1,290 | $1,347 | $126.64 | 9.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 270 | $87,210 | $24,126 | 27.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 32 | 164 | $170,232 | $16,384 | 9.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 42 | 84 | $42,504 | $10,676 | 25.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 25 | 25 | $16,475 | $3,941 | 23.9% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 25 | 227 | $43,357 | $2,743 | 6.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2022 | 13 | 49 | $26,215 | $2,474 | 9.4% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 13 | 66 | $17,490 | $1,454 | 8.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 18 | 45 | $4,050 | $480.59 | 11.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 22 | 1,454 | $727.00 | $133.99 | 18.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 71 | 127 | $39,878 | $12,569 | 31.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 24 | 116 | $35,032 | $9,689 | 27.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 18 | 69 | $69,690 | $7,630 | 10.9% |
About Dr. Jasleen Randhawa, M.D
Dr. Jasleen Randhawa, M.D is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/15/2008. The National Provider Identifier (NPI) number assigned to this provider is 1134305675.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jasleen Randhawa, M.D has received a total of $8,965 in payments from pharmaceutical and medical device companies, with $22.41 received in 2024. These payments were reported across 30 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($6,475).
As a Medicare-enrolled provider, Randhawa has provided services to 985 Medicare beneficiaries, totaling 6,537 services with total Medicare billing of $222,471. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hospitalist, Hematology & Oncology
- Location Houston, TX
- Active Since 01/15/2008
- Last Updated 07/21/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1134305675
Products in Payments
- ABL001X (Drug) $557.00
- ABL002 (Drug) $295.97
- TECFIDERA (Drug) $131.60
- MYLOTARG (Biological) $85.99
- TASIGNA (Drug) $44.37
- Blincyto (Biological) $25.75
- PROMACTA (Drug) $22.20
- CRESEMBA (Drug) $21.69
- BOSULIF (Drug) $20.53
- SOLIRIS (Drug) $16.56
- Hizentra (Biological) $14.16
- NINLARO (Drug) $13.55
- LUPRON DEPOT (Drug) $13.50
- IBRANCE (Drug) $12.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001